Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Operating Expenses (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Operating Expenses for 5 consecutive years, with $20.1 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 65.95% to $20.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $98.5 million through Dec 2025, down 56.77% year-over-year, with the annual reading at $98.4 million for FY2025, 56.75% down from the prior year.
  • Operating Expenses for Q4 2025 was $20.1 million at Lexicon Pharmaceuticals, down from $26.4 million in the prior quarter.
  • The five-year high for Operating Expenses was $65.4 million in Q3 2024, with the low at $20.1 million in Q4 2025.
  • Average Operating Expenses over 3 years is $41.6 million, with a median of $45.5 million recorded in 2023.
  • The sharpest move saw Operating Expenses soared 48.98% in 2024, then tumbled 65.95% in 2025.
  • Over 3 years, Operating Expenses stood at $47.4 million in 2023, then rose by 24.43% to $58.9 million in 2024, then crashed by 65.95% to $20.1 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $20.1 million, $26.4 million, and $25.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.